ACAD - ACADIA Pharmaceuticals Inc. Stock Price and Quote

ACAD [NASD]

Index	-	P/E	-	EPS (ttm)	-1.34	Insider Own	0.10%	Shs Outstand	161.85M	Perf Week	7.29%
Market Cap	3.22B	Forward P/E	-	EPS next Y	-0.88	Insider Trans	-12.63%	Shs Float	161.70M	Perf Month	15.45%
Income	-217.30M	PEG	-	EPS next Q	-0.24	Inst Own	94.90%	Short Float / Ratio	4.96% / 6.89	Perf Quarter	34.14%
Sales	511.50M	P/S	6.30	EPS this Y	41.60%	Inst Trans	0.92%	Short Interest	8.01M	Perf Half Y	20.92%
Book/sh	2.63	P/B	7.54	EPS next Y	32.80%	ROA	-34.20%	Target Price	18.74	Perf Year	-15.08%
Cash/sh	2.68	P/C	7.39	EPS next 5Y	25.00%	ROE	-47.10%	52W Range	12.24 - 28.06	Perf YTD	24.87%
Dividend	-	P/FCF	-	EPS past 5Y	14.90%	ROI	-31.60%	52W High	-29.14%	Beta	0.59
Dividend %	-	Quick Ratio	4.40	Sales past 5Y	94.60%	Gross Margin	98.00%	52W Low	62.42%	ATR	0.62
Employees	510	Current Ratio	4.50	Sales Q/Q	-0.70%	Oper. Margin	-43.40%	RSI (14)	70.80	Volatility	2.83% 3.56%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-86.70%	Profit Margin	-42.50%	Rel Volume	0.64	Prev Close	19.83
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 02 AMC	Payout	-	Avg Volume	1.16M	Price	19.88
Recom	2.60	SMA20	7.66%	SMA50	19.43%	SMA200	20.32%	Volume	248,645	Change	0.25%

Jan-03-23

Upgrade

Guggenheim

Neutral → Buy

$22

Nov-04-22

Downgrade

Goldman

Neutral → Sell

$15 → $12

Nov-01-22

Initiated

Loop Capital

Hold

$17

Aug-08-22

Downgrade

Citigroup

Buy → Neutral

$19 → $15

Aug-05-22

Downgrade

Citigroup

Buy → Neutral

$19 → $15

Jun-21-22

Downgrade

Jefferies

Buy → Underperform

$25 → $10

Jun-16-22

Upgrade

Jefferies

Hold → Buy

$25

Mar-16-22

Upgrade

Canaccord Genuity

Hold → Buy

$30 → $31

Feb-09-22

Upgrade

H.C. Wainwright

Neutral → Buy

$36

Jan-05-22

Upgrade

Citigroup

Neutral → Buy

$30

Show Previous Ratings

Jan-09-23 09:00AM	Acadia Pharmaceuticals Appoints Doug Williamson, M.D., as Executive Vice President, Head of Research and Development Business Wire
Jan-03-23 11:58AM	Investors in ACADIA Pharmaceuticals (NASDAQ:ACAD) from three years ago are still down 62%, even after 4.1% gain this past week Simply Wall St.
09:00AM	Newly Published Retrospective Analysis Showed Lower All-Cause Mortality Risk Among Parkinsons Disease Psychosis Patients Treated with NUPLAZID® (pimavanserin) Compared to Those Treated with Other Atypical Antipsychotics Business Wire
08:28AM	Acadia Pharmaceuticals Bulls Will Need to Be Patient for Now TheStreet.com
Dec-21-22 04:05PM	Acadia Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 Business Wire
04:05PM	Loading…
Nov-08-22 04:05PM	Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences Business Wire +5.59%
Nov-03-22 12:23PM	Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss Zacks -6.97%
Nov-02-22 05:35PM	Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:05PM	Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results Business Wire
Nov-01-22 10:04AM	Is a Surprise Coming for Acadia Pharmaceuticals (ACAD) This Earnings Season? Zacks
Oct-27-22 04:05PM	Acadia Pharmaceuticals Announces Planned Retirement of President Srdjan (Serge) Stankovic Business Wire
10:02AM	Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-26-22 10:02AM	Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? Zacks
09:11AM	Breakeven On The Horizon For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Simply Wall St.
Oct-20-22 04:05PM	Acadia Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022 Business Wire
12:02PM	Loading…
Oct-19-22 12:02PM	AVEO Pharmaceuticals (AVEO) Inks Deal to be Acquired by LG Chem Zacks
Oct-13-22 07:30AM	Acadia Pharmaceuticals Appoints Adora Ndu, Pharm.D., J.D. to its Board of Directors Business Wire
Oct-12-22 10:57AM	Acadia (ACAD) Thrives on Nuplazid, Overdependence a Concern Zacks
Oct-06-22 01:36PM	Acadia (ACAD) Rises More Than 14% in 3 Months: Here's Why Zacks
Oct-04-22 02:19PM	Why Acadia Pharmaceuticals Stock's Rally Could Have Legs Schaeffer's Investment Research +5.99%
07:30AM	Acadia Pharmaceuticals Recognizes Rett Syndrome Awareness Month and Launches New Awareness Campaign, Rett Revealed Business Wire
Sep-13-22 08:44AM	Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review Zacks -5.64%
Sep-12-22 07:30AM	Acadia Pharmaceuticals Announces Trofinetide New Drug Application for the Treatment of Rett Syndrome has been Accepted for Filing and Review by U.S. FDA Business Wire
Sep-07-22 11:30AM	Acadia (ACAD) Down 0.6% Since Last Earnings Report: Can It Rebound? Zacks
Sep-01-22 09:03AM	Acadia Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
Aug-30-22 09:55AM	Wall Street Analysts Believe Acadia (ACAD) Could Rally 26%: Here's is How to Trade Zacks
Aug-26-22 12:00PM	Acadia (ACAD) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Aug-09-22 01:24PM	Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data Benzinga
11:06AM	Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates Zacks
Aug-08-22 05:35PM	Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM	Loading…
04:05PM	Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results Business Wire
Aug-05-22 07:55AM	FDA Asks For Additional Study For Acadia's Pimavanserin In Alzheimer's-Associated Delusions Benzinga +5.25%
Aug-04-22 11:39PM	UPDATE 1-U.S. FDA declines to approve expanded use of Acadia's antipsychotic drug Reuters
11:05PM	Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Alzheimers Disease Psychosis Business Wire
Aug-01-22 10:01AM	Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jul-27-22 08:23AM	Investors five-year losses grow to 52% as the stock sheds US$212m this past week Simply Wall St.
Jul-25-22 04:05PM	Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022 Business Wire
Jul-19-22 11:22AM	Acadia (ACAD) Files an NDA for Its Rett Syndrome Candidate Zacks
Jul-18-22 04:07PM	Acadia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Trofinetide for the Treatment of Rett Syndrome Business Wire
Jul-08-22 11:14AM	Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why Zacks
Jun-21-22 12:07PM	Why Acadia Pharmaceuticals Stock Is Crashing Today Motley Fool -33.32%
08:27AM	Why Acadia Pharma Shares Are Plunging Today Benzinga
07:56AM	Acadia's stock down 30% in premarket trading on Tuesday after last week's FDA committee vote MarketWatch
Jun-17-22 08:00PM	Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimers Disease Psychosis Business Wire
07:14AM	Acadia Pharmaceuticals stock halted for FDA panel to review treatment for hallucinations stemming from Alzheimer's disease psychosis MarketWatch
07:05AM	Acadia Pharmaceuticals Stock Trading Halted Today Business Wire
Jun-16-22 03:42PM	HC Wainwright Sees Opportunity For Acadia's Alzheimer's Candidate Benzinga
10:42AM	Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA Zacks
Jun-15-22 04:53PM	Why Acadia Pharma Surged Despite A Negative FDA Take On Its Lead Drug Investor's Business Daily +15.51%
02:55PM	Why ACADIA Pharmaceuticals Shares Are Trading Higher Today? Benzinga
01:07PM	Why Acadia Pharmaceuticals Spiked Today Motley Fool
Jun-03-22 11:31AM	Why Is Acadia (ACAD) Down 13.9% Since Last Earnings Report? Zacks +10.43%
May-19-22 09:01AM	Breakeven On The Horizon For ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Simply Wall St.
May-05-22 10:06AM	Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates Zacks -5.33%
May-04-22 06:15PM	Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:05PM	Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results Business Wire
May-03-22 04:05PM	Acadia Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire
May-02-22 04:05PM	Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimers Disease Psychosis Scheduled for June 17, 2022 Business Wire +5.97%
06:36AM	Zymeworks Inc. (ZYME) Surges 23.2%: Is This an Indication of Further Gains? Zacks
Apr-27-22 03:03PM	Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-21-22 09:09AM	9 Healthcare Stocks to Invest In Today According to Stanley Druckenmiller Insider Monkey
09:00AM	Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022 Business Wire
Apr-19-22 05:52PM	10 Trending Stocks to Watch Today Insider Monkey
03:49PM	Analysts Say Acadia's Negative Pain Data Increases Focus On Pimavanserin For Alzheimer's-Related Psychosis Benzinga
12:02PM	Acadia (ACAD) Stock Down as Pain Candidate Misses Study Goal Zacks
06:10AM	Why Acadia Pharma Shares Are Falling Today Benzinga
Apr-18-22 04:05PM	Acadia Pharmaceuticals Announces Top-Line Results from Phase 2 Study Evaluating ACP-044 for the Treatment of Acute Postoperative Pain Business Wire
Mar-30-22 11:30AM	Why Is Acadia (ACAD) Up 1% Since Last Earnings Report? Zacks
Mar-25-22 02:26PM	Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating Investor's Business Daily
Mar-22-22 09:00AM	Acadia Pharmaceuticals to Present Late-Breaking Data at the 2022 American Academy of Neurology Annual Meeting (AAN) Business Wire
Mar-10-22 04:05PM	Acadia Pharmaceuticals to Present at the 1st Annual Needham Virtual Neuroscience Forum on March 16, 2022 Business Wire
11:50AM	Acadia (ACAD) Stock Up on FDA's Action Date for Nuplazid sNDA Zacks
Mar-09-22 08:30AM	Acadia Pharmaceuticals Announces August 4, 2022 Action Date for Resubmitted Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimers Disease Psychosis Business Wire +10.17%
Mar-03-22 09:00AM	Acadia Pharmaceuticals to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022 Business Wire
Mar-01-22 09:43AM	Acadia (ACAD) Q4 Earnings & Revenues Fall Shy of Estimates Zacks
Feb-28-22 05:35PM	Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:05PM	Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results Business Wire
Feb-21-22 03:00PM	Will Acadia Pharmaceuticals (ACAD) Report Negative Earnings Next Week? What You Should Know Zacks
Feb-17-22 04:28AM	The past year for ACADIA Pharmaceuticals (NASDAQ:ACAD) investors has not been profitable Simply Wall St.
Feb-16-22 09:00AM	Acadia Pharmaceuticals Announces Resubmission of Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) to Treat Alzheimers Disease Psychosis Business Wire
08:30AM	Here's How Much a $1000 Investment in Acadia Pharmaceuticals Made 10 Years Ago Would Be Worth Today Zacks
Feb-14-22 09:00AM	Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022 Business Wire
Feb-11-22 09:00AM	Acadia Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022 Business Wire
Feb-02-22 01:38PM	Emerald Advisers, Llc Buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA Pharmaceuticals ... GuruFocus.com
01:38PM	Emerald Mutual Fund Advisers Trust Buys Customers Bancorp Inc, Herc Holdings Inc, ACADIA ... GuruFocus.com
Jan-13-22 11:13AM	Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why Zacks
Jan-11-22 11:56AM	Acadia (ACAD) Partners With Stoke for CNS Disorder Therapies Zacks
Jan-10-22 01:20PM	RNA startup inks deal worth up to $967M American City Business Journals
07:00AM	Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases Business Wire
Dec-22-21 05:24PM	Why Acadia Pharmaceuticals Stock Climbed More Than 10% Wednesday Motley Fool +11.52%
09:00AM	Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022 Business Wire
Dec-21-21 04:12PM	Why This Acadia Pharmaceuticals Move Has Analysts Split And Shares Down 20% Investor's Business Daily -20.82%
11:29AM	ACADIA (ACAD) Up on Resubmission Plan for Nuplazid sNDA to FDA Zacks
Dec-20-21 04:05PM	Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin) Business Wire +5.16%
Dec-14-21 09:00AM	Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer Business Wire
Dec-11-21 05:38AM	Penn Series Small Cap Growth Fund Buys Core & Main Inc, Clear Secure Inc, Inotiv Inc, Sells ... GuruFocus.com
Dec-08-21 08:35AM	Biotech Stock Roundup: ACAD Up on Study Results, BHVN's Pipeline Update & More Zacks
Dec-07-21 12:29PM	ACADIA's (ACAD) Rett Syndrome Candidate Meets Goal in Study Zacks +9.90%
08:33AM	Why Acadia Pharmaceuticals Stock Is Rocketing Today Motley Fool
07:25AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday InvestorPlace

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brege Laura	Director	Jan 12	Option Exercise	17.01	12,500	212,625	12,500	Jan 17 05:17 PM
BAKER BROS. ADVISORS LP	Director	Jan 12	Option Exercise	5.22	30,000	156,600	38,484,981	Jan 17 04:22 PM
Brege Laura	Director	Jan 12	Sale	18.25	12,500	228,125	0	Jan 17 05:17 PM
DAVIS STEPHEN	CEO	Jan 09	Sale	17.13	3,904	66,877	84,633	Jan 10 08:38 PM
KIM AUSTIN D.	EVP,General Counsel, Secretary	Jan 09	Sale	17.13	589	10,090	18,697	Jan 10 08:20 PM
Teehan Brendan	EVP, COO, Head of Commercial	Jan 09	Sale	17.13	532	9,113	4,549	Jan 10 08:30 PM
Stankovic Srdjan R.	President	Nov 21	Sale	15.07	1,847	27,834	61,234	Nov 22 04:34 PM
Stankovic Srdjan R.	President	Oct 15	Sale	15.81	1,326	20,964	56,831	Oct 18 09:22 PM
DAVIS STEPHEN	CEO	Oct 15	Sale	15.81	2,804	44,331	79,009	Oct 18 09:16 PM
Schneyer Mark C.	EVP, Chief Financial Officer	Jun 09	Sale	17.91	653	11,695	3,342	Jun 10 08:51 PM
Schneyer Mark C.	EVP, Chief Financial Officer	Jun 08	Option Exercise	0.00	1,893	0	3,995	Jun 10 08:51 PM
DAVIS STEPHEN	CEO	May 02	Sale	18.18	5,483	99,691	75,875	May 03 08:58 PM
Stankovic Srdjan R.	President	May 02	Sale	18.18	2,865	52,091	55,188	May 03 08:55 PM
KIM AUSTIN D.	EVP,General Counsel, Secretary	May 02	Sale	18.18	894	16,255	16,742	May 03 08:51 PM
Teehan Brendan	EVP, COO, Head of Commercial	May 02	Sale	18.18	552	10,036	3,437	May 03 08:47 PM
Kihara James	Principal Accounting Officer	Apr 08	Sale	27.05	1,025	27,726	2,433	Apr 11 08:02 PM
Stankovic Srdjan R.	President	Feb 23	Option Exercise	0.00	4,919	0	49,938	Feb 25 05:41 PM
Teehan Brendan	EVP, COO, Head of Commercial	Feb 23	Option Exercise	0.00	1,106	0	2,894	Feb 25 05:45 PM
Kihara James	Principal Accounting Officer	Feb 23	Option Exercise	0.00	840	0	840	Feb 25 05:45 PM
DAVIS STEPHEN	CEO	Feb 23	Option Exercise	0.00	10,945	0	69,661	Feb 25 05:40 PM
KIM AUSTIN D.	EVP & General Counsel	Feb 23	Option Exercise	0.00	2,213	0	15,413	Feb 25 05:42 PM
Teehan Brendan	EVP, COO, Head of Commercial	Feb 23	Sale	23.80	472	11,234	2,422	Feb 25 05:45 PM
Stankovic Srdjan R.	President	Feb 23	Sale	23.80	1,501	35,724	48,437	Feb 25 05:41 PM
Kihara James	Principal Accounting Officer	Feb 23	Sale	23.80	359	8,544	481	Feb 25 05:45 PM
KIM AUSTIN D.	EVP & General Counsel	Feb 23	Sale	23.80	782	18,612	14,631	Feb 25 05:42 PM
DAVIS STEPHEN	CEO	Feb 23	Sale	23.80	3,928	93,486	65,733	Feb 25 05:40 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience